These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11051228)

  • 1. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy.
    Shalev M; Thompson TC; Frolov A; Lippman SM; Hong WK; Fritsche H; Kadmon D
    Clin Cancer Res; 2000 Oct; 6(10):3845-9. PubMed ID: 11051228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay.
    Schild SE; Wong WW; Novicki DE; Ferrigni RG; Swanson SK
    Urology; 1996 Jun; 47(6):878-81. PubMed ID: 8677580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation.
    Schaefer U; Witt F; Schueller P; Micke O; Willich N
    Anticancer Res; 2000; 20(6D):4989-92. PubMed ID: 11326654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radiation for a rising PSA following radical prostatectomy.
    Maier J; Forman J; Tekyi-Mensah S; Bolton S; Patel R; Pontes JE
    Urol Oncol; 2004; 22(1):50-6. PubMed ID: 14969805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
    Beer TM; Lemmon D; Lowe BA; Henner WD
    Cancer; 2003 Mar; 97(5):1217-24. PubMed ID: 12599228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of determining prostate specific antigen in follow-up of prostatic cancer].
    Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C
    Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
    Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL
    Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered prostate specific antigen reference range after transurethral resection of the prostate.
    Wolff JM; Boekels O; Borchers H; Jakse G; Rohde D
    Anticancer Res; 2000; 20(6D):4977-80. PubMed ID: 11326651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
    Smith MR; Manola J; Kaufman DS; George D; Oh WK; Mueller E; Slovin S; Spiegelman B; Small E; Kantoff PW
    Cancer; 2004 Oct; 101(7):1569-74. PubMed ID: 15468186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of radiotherapy on patients with prostate specific antigen failure after radical prostatectomy].
    Sakata Y; Hasegawa Y; Wakita T; Hayashi N; Fuwa N
    Hinyokika Kiyo; 2004 Jul; 50(7):463-7. PubMed ID: 15334889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.